Literature DB >> 16904380

The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer.

Tracy R Daniels1, Tracie Delgado, Jose A Rodriguez, Gustavo Helguera, Manuel L Penichet.   

Abstract

The transferrin receptor (TfR) is a cell membrane-associated glycoprotein involved in the cellular uptake of iron and in the regulation of cell growth. Iron uptake occurs via the internalization of iron-loaded transferrin (Tf) mediated by the interaction with the TfR. In addition, the TfR may also contain other growth regulatory properties in certain normal and malignant cells. The elevated levels of TfR in malignancies, its relevance in cancer, and the extracellular accessibility of this molecule make it an excellent antigen for the treatment of cancer using antibodies. The TfR can be targeted by monoclonal antibodies specific for the extracellular domain of the receptor. In this review, we summarize advancements in the basic physiology of the TfR including structure, function, and expression. We also discuss the efficacy of targeting the TfR using cytotoxic antibodies that inhibit cell growth and/or induce apoptosis in targeted malignant cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16904380     DOI: 10.1016/j.clim.2006.06.010

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  204 in total

1.  Multivalent display and receptor-mediated endocytosis of transferrin on virus-like particles.

Authors:  Deboshri Banerjee; Allen P Liu; Neil R Voss; Sandra L Schmid; M G Finn
Journal:  Chembiochem       Date:  2010-06-14       Impact factor: 3.164

2.  Self-assembled Targeting of Cancer Cells by Iron(III)-doped, Silica Nanoparticles.

Authors:  K K Pohaku Mitchell; S Sandoval; M J Cortes-Mateos; J G Alfaro; A C Kummel; W C Trogler
Journal:  J Mater Chem B       Date:  2014-12-07       Impact factor: 6.331

3.  Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack.

Authors:  Marc Cinci; Srinivas Mamidi; Wenhan Li; Volker Fehring; Michael Kirschfink
Journal:  Target Oncol       Date:  2014-11-15       Impact factor: 4.493

4.  Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis.

Authors:  Eriko Suzuki; Tracy R Daniels; Gustavo Helguera; Manuel L Penichet; Kazuo Umezawa; Benjamin Bonavida
Journal:  Int J Oncol       Date:  2010-05       Impact factor: 5.650

Review 5.  Clinical developments in nanotechnology for cancer therapy.

Authors:  Jeremy D Heidel; Mark E Davis
Journal:  Pharm Res       Date:  2010-06-12       Impact factor: 4.200

Review 6.  Strategies in the design of nanoparticles for therapeutic applications.

Authors:  Robby A Petros; Joseph M DeSimone
Journal:  Nat Rev Drug Discov       Date:  2010-07-09       Impact factor: 84.694

Review 7.  Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence.

Authors:  Alyssa B Chinen; Chenxia M Guan; Jennifer R Ferrer; Stacey N Barnaby; Timothy J Merkel; Chad A Mirkin
Journal:  Chem Rev       Date:  2015-08-27       Impact factor: 60.622

8.  Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.

Authors:  Lai Sum Leoh; Kouki Morizono; Kathleen M Kershaw; Irvin S Y Chen; Manuel L Penichet; Tracy R Daniels-Wells
Journal:  J Gene Med       Date:  2014 Jan-Feb       Impact factor: 4.565

9.  Exploring transferrin-receptor interactions at the single-molecule level.

Authors:  Alexandre Yersin; Toshiya Osada; Atsushi Ikai
Journal:  Biophys J       Date:  2007-09-14       Impact factor: 4.033

10.  In vivo molecular mapping of the tumor microenvironment in an azoxymethane-treated mouse model of colon carcinogenesis.

Authors:  Sarah J Leung; Photini S Rice; Jennifer K Barton
Journal:  Lasers Surg Med       Date:  2014-12-09       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.